CBPO : Summary for China Biologic Products, Inc. - Yahoo Finance

U.S. Markets open in 6 hrs 47 mins

China Biologic Products, Inc. (CBPO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
107.32+0.43 (+0.40%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close106.89
Bid0.00 x
Ask0.00 x
Day's Range105.91 - 108.00
52 Week Range100.53 - 137.39
Avg. Volume169,329
Market Cap2.91B
PE Ratio (TTM)29.43
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks5 days ago

    New Strong Sell Stocks for January 18th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday

  • PR Newswire17 days ago

    China Biologic to Build New Collection Station and New Branch Collection Facility in Shandong Province

    BEIJING, Jan. 6, 2017 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd. ("Shandong Taibang") received two approvals from the Shandong Provincial Health and Family Planning Commission on December 30, 2016 to build a new plasma collection station and a new branch collection facility, respectively, in Shandong Province. The new plasma collection station will be located in Ju County in Rizhao City, while the new branch plasma collection facility will be located in Feicheng County in Tai'an City and operated under the Company's Ningyang plasma collection station, which was established in Tai'an City in July 2011.

  • PR Newswire19 days ago

    China Biologic to Attend the 35th Annual J.P. Morgan Healthcare Conference

    China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company will participate in the 35th Annual J.P. Morgan Healthcare Conference, to be held at the Westin St. Francis Hotel, San Francisco, California, January 9-12, 2017. Mr. David Gao, Chairman and Chief Executive Officer, Mr. Ming Yang, Chief Financial Officer, and Mr. Ming Yin, Senior Vice President of China Biologic, will meet with investors at the event. The Company reiterates its full year forecast of total sales growth of 22% to 24% in RMB terms and non-GAAP adjusted net income growth of 33% to 35% in RMB terms over the Company's 2015 financial results.